From Yahoo Finance: 2025-06-06 14:10:00

Sanofi (NASDAQ:SNY) saw a 5% drop despite positive results from AERIFY-1 trial with Regeneron Pharmaceuticals. This contrasts with a 2% market rise. Long-term performance remains strong with 19.59% total return over five years. Analysts project a 18.5% potential upside with share price at €95.9 and consensus target of €117.17 by 2028.

While SNY shows promise, some AI stocks may offer higher returns with limited downside risk. A report highlights an extremely cheap AI stock benefiting from Trump tariffs and onshoring. For more insights on investment opportunities, explore articles on the best cancer stocks for long-term gains and the most oversold stocks to buy according to billionaires. No disclosure mentioned.



Read more at Yahoo Finance: Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success